Youcare Pharmaceutical (SH:688658) 智通财经网·2025-11-05 08:18Core Viewpoint - YKYY013 injection, developed by Yuyuan Pharmaceutical's subsidiary and Hangzhou Tianlong Pharmaceutical, has received approval from NMPA for clinical trials targeting chronic hepatitis B virus infection [1] Company Summary - Yuyuan Pharmaceutical's subsidiary, Beijing Yuyuan Kechuang Pharmaceutical Technology Co., Ltd., and Hangzhou Tianlong Pharmaceutical have jointly developed YKYY013 injection [1] - The drug is a chemically synthesized double-stranded siRNA that utilizes N-acetylgalactosamine (GalNAc) as a ligand [1] - The mechanism of action involves RNA interference to silence the HBV genome's messenger RNA, thereby inhibiting the production of hepatitis B viral proteins and replication [1] Industry Summary - The approval for YKYY013 marks a significant advancement in the treatment options for chronic hepatitis B virus infection [1] - The drug aims to create conditions for immune reconstitution in patients, potentially leading to functional cure for hepatitis B [1]